Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination ...

Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...

Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

Pyxis One, a start-up providing AI infrastructure for marketing, today announced the appointment of Neel Pandya as the new chief executive officer of its APAC business. Shubham Mishra, who helmed ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...

Shares of Pyxis Oncology declined after the company logged a steeper first-quarter loss, narrowly missing Wall Street's expectations. The stock slid 15% to $2.24 on Thursday. Shares have surged 94% ...

Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...

Advanced digital film camera in a versatile design with revolutionary full frame 12K RGBW sensor in EF, PL or L-Mount, Blackmagic RAW and global media sync with Blackmagic Cloud! Blackmagic PYXIS 12K ...